← Eichor
Study identifier: NCT05834803 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.

Condition: Renovascular Hypertension · Renovascular Hypertension With Renal Failure · Heart Failure  ·  Sponsor: University of Aarhus

PhaseNA
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on: * Blood pressure * Kidney function * Hospitalizations for heart failure

This description comes directly from the study's public registry record.

Talk to the study team

Sebastian Nielsen, MD  ·  +45 23100484  ·  sebane@rm.dk

Mark Reinhard, MD, PhD  ·  +45 40460321  ·  m.reinhard@dadlnet.dk

Always discuss trial participation with your own doctor first.

Locations (3)

Aarhus University HospitalAarhus N, DenmarkRecruiting
RigshospitaletCopenhagen, DenmarkRecruiting
Odense University HospitalOdense C, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05834803